154 related articles for article (PubMed ID: 11229856)
1. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy.
Kern WV; Heiss M; Steinbach G
Clin Infect Dis; 2001 Mar; 32(5):832-5. PubMed ID: 11229856
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-8 serum levels at fever onset in patients with neutropenia predict early medical complications.
Engel A; Knoll S; Kern P; Kern WV
Infection; 2005 Oct; 33(5-6):380-2. PubMed ID: 16258872
[TBL] [Abstract][Full Text] [Related]
3. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia.
Lehrnbecher T; Venzon D; de Haas M; Chanock SJ; Kühl J
Clin Infect Dis; 1999 Aug; 29(2):414-9. PubMed ID: 10476751
[TBL] [Abstract][Full Text] [Related]
4. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia.
Ammann RA; Hirt A; Lüthy AR; Aebi C
Pediatr Infect Dis J; 2004 Jan; 23(1):61-7. PubMed ID: 14743049
[TBL] [Abstract][Full Text] [Related]
5. Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever.
Chayakulkeeree M; Thamlikitkul V
J Med Assoc Thai; 2003 Mar; 86(3):212-23. PubMed ID: 12757060
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.
El-Maghraby SM; Moneer MM; Ismail MM; Shalaby LM; El-Mahallawy HA
J Pediatr Hematol Oncol; 2007 Mar; 29(3):131-6. PubMed ID: 17356388
[TBL] [Abstract][Full Text] [Related]
7. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for Gram-negative bacterial infections in febrile neutropenia.
Cordonnier C; Herbrecht R; Buzyn A; Leverger G; Leclercq R; Nitenberg G; Bastuji-Garin S;
Haematologica; 2005 Aug; 90(8):1102-9. PubMed ID: 16079110
[TBL] [Abstract][Full Text] [Related]
9. An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients.
Engel A; Mack E; Kern P; Kern WV
Infection; 1998; 26(4):213-21. PubMed ID: 9717678
[TBL] [Abstract][Full Text] [Related]
10. Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade.
Kanafani ZA; Dakdouki GK; El-Chammas KI; Eid S; Araj GF; Kanj SS
Int J Infect Dis; 2007 Sep; 11(5):450-3. PubMed ID: 17337226
[TBL] [Abstract][Full Text] [Related]
11. Bacteraemia in febrile neutropenic cancer patients.
Klastersky J; Ameye L; Maertens J; Georgala A; Muanza F; Aoun M; Ferrant A; Rapoport B; Rolston K; Paesmans M
Int J Antimicrob Agents; 2007 Nov; 30 Suppl 1():S51-9. PubMed ID: 17689933
[TBL] [Abstract][Full Text] [Related]
12. Bloodstream infections in cancer patients with febrile neutropenia.
Feld R
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S30-3. PubMed ID: 18778919
[TBL] [Abstract][Full Text] [Related]
13. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
14. Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.
Chee L; Brown M; Sasadeusz J; MacGregor L; Grigg AP
J Infect; 2008 Apr; 56(4):227-33. PubMed ID: 18342947
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia.
Tamura K; Imajo K; Akiyama N; Suzuki K; Urabe A; Ohyashiki K; Tanimoto M; Masaoka T;
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S15-24. PubMed ID: 15250016
[TBL] [Abstract][Full Text] [Related]
16. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Craig M; Cumpston AD; Hobbs GR; Devetten MP; Sarwari AR; Ericson SG
Bone Marrow Transplant; 2007 Apr; 39(8):477-82. PubMed ID: 17322937
[TBL] [Abstract][Full Text] [Related]
17. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
Ritchie S; Palmer S; Ellis-Pegler R
Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
Oude Nijhuis C; Kamps WA; Daenen SM; Gietema JA; van der Graaf WT; Groen HJ; Vellenga E; Ten Vergert EM; Vermeulen KM; de Vries-Hospers HG; de Bont ES
J Clin Oncol; 2005 Oct; 23(30):7437-44. PubMed ID: 16234511
[TBL] [Abstract][Full Text] [Related]
19. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.
Düzova A; Kutluk T; Kanra G; Büyükpamukçu M; Akyüz C; Seçmeer G; Ceyhan M
Turk J Pediatr; 2001; 43(2):105-9. PubMed ID: 11432485
[TBL] [Abstract][Full Text] [Related]
20. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004.
Paul M; Gafter-Gvili A; Leibovici L; Bishara J; Levy I; Yaniv I; Shalit I; Samra Z; Pitlik S; Konigsberger H; Weinberger M
Isr Med Assoc J; 2007 Jun; 9(6):424-9. PubMed ID: 17642387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
